drugset / Trial / NCT05829239
ADI-PEG20, Obesity and Prediabetes
Phase 2
Withdrawn
Washington University School of Medicine
Children's Discovery Institute · collabPolaris Pharmaceuticals, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Th purpose of this study is to determine whether ADI-PEG20 (PEGylated arginine deiminase), an arginine catabolizing enzyme preparation, improves insulin sensitivity, mitochondrial respiration, and energy utilization in adolescents with prediabetes.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2024-04-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | 18 mg/m2 | Intramuscular |